^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFRvIII-targeted CAR-T immunotherapy

    Related drugs:
    Apply
    CARv3-TEAM-E T Cells in Glioblastoma (NCT05660369)
    Phase 1
    Marcela V. Maus, M.D.,Ph.D.
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/22/2023
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    MGMT
    |
    EGFR amplification • EGFRvIII mutation
    |
    CARv3-TEAM-E T cells
    CART-EGFRvIII + Pembrolizumab in GBM (NCT03726515)
    Phase 1
    University of Pennsylvania
    Completed
    Last update posted :
    06/22/2023
    Initiation :
    03/11/2019
    Primary completion :
    02/27/2021
    Completion :
    02/27/2021
    EGFR • MGMT • TERT
    |
    EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation
    |
    Keytruda (pembrolizumab) • LXF821
    Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (NCT03941626)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    02/04/2021
    Initiation :
    09/01/2019
    Primary completion :
    05/01/2021
    Completion :
    12/01/2021
    HLA-A • MSLN • CTAG1B
    |
    HLA-A*02:01 • MSLN positive • HLA-A positive
    |
    cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    12/11/2019
    Initiation :
    03/01/2018
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
    |
    HLA-A*02:01 • CD19 expression • HLA-A positive
    |
    cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy